Clinical Trial Update: Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 compassionate use trial update for beraprost sodium 314d modified release in pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• beraprost sodium 314d modified release (beraprost sodium 314d modified release)

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED